Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aptevo Therapeutics Inc 2401 4TH AVENUE SUITE 1050 SEATTLE WA 98121 USA

www.aptevotherapeutics.com Employees: 42 P: 206-838-0500 F: 206-838-0503

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.

Key Statistics

Overview:

Market Capitalization, $K 15,672
Enterprise Value, $K 6,962
Shares Outstanding, K 16,850
Annual Sales, $ 0 K
Annual Net Income, $ -24,130 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,550 K
EBIT, $ -26,700 K
EBITDA, $ -26,350 K
60-Month Beta 1.41
% of Insider Shareholders 0.01%
% of Institutional Shareholders 8.06%
Float, K 16,848
% Float 99.99%
Short Interest 391
Short Float 2.32%
Short Volume Ratio 0.65

Growth:

1-Year Return -99.41%
3-Year Return -100.00%
5-Year Return -100.00%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 99.64%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.23 on 11/06/25
Next Earnings Date 02/13/26
Earnings Per Share ttm -98.43
EPS Growth vs. Prev Qtr 73.45%
EPS Growth vs. Prev Year 99.36%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 05/27/25

APVO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -389.34%
Return-on-Assets % -159.11%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.81
Book Value/Share 1.26
Interest Coverage -1.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar